AR082907A1 - Sistemas terapeuticos transdermicos con lamina de proteccion inhibidora de la cristalizacion (release liner) - Google Patents

Sistemas terapeuticos transdermicos con lamina de proteccion inhibidora de la cristalizacion (release liner)

Info

Publication number
AR082907A1
AR082907A1 ARP110103250A ARP110103250A AR082907A1 AR 082907 A1 AR082907 A1 AR 082907A1 AR P110103250 A ARP110103250 A AR P110103250A AR P110103250 A ARP110103250 A AR P110103250A AR 082907 A1 AR082907 A1 AR 082907A1
Authority
AR
Argentina
Prior art keywords
matrix
transdermal therapeutic
crystallization
inhibitant
release liner
Prior art date
Application number
ARP110103250A
Other languages
English (en)
Spanish (es)
Inventor
Stefan Bracht
Ildiko Terebesi
Thomas Langguth
Original Assignee
Bayer Pharma Aktiengellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44653285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082907(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengellschaft filed Critical Bayer Pharma Aktiengellschaft
Publication of AR082907A1 publication Critical patent/AR082907A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP110103250A 2010-09-06 2011-09-06 Sistemas terapeuticos transdermicos con lamina de proteccion inhibidora de la cristalizacion (release liner) AR082907A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010040299A DE102010040299A1 (de) 2010-09-06 2010-09-06 Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)

Publications (1)

Publication Number Publication Date
AR082907A1 true AR082907A1 (es) 2013-01-16

Family

ID=44653285

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103250A AR082907A1 (es) 2010-09-06 2011-09-06 Sistemas terapeuticos transdermicos con lamina de proteccion inhibidora de la cristalizacion (release liner)

Country Status (33)

Country Link
US (2) US8557279B2 (enExample)
EP (1) EP2613771A1 (enExample)
JP (2) JP6104800B2 (enExample)
KR (1) KR20130114127A (enExample)
CN (1) CN103079549B (enExample)
AP (1) AP3586A (enExample)
AR (1) AR082907A1 (enExample)
AU (1) AU2011298892B2 (enExample)
BR (1) BR112013005305A2 (enExample)
CA (1) CA2810103C (enExample)
CL (1) CL2013000636A1 (enExample)
CO (1) CO6690753A2 (enExample)
CR (1) CR20130098A (enExample)
CU (1) CU24172B1 (enExample)
DE (1) DE102010040299A1 (enExample)
DO (1) DOP2013000053A (enExample)
EA (1) EA032575B1 (enExample)
EC (1) ECSP13012477A (enExample)
GT (1) GT201300062A (enExample)
IL (2) IL224980A (enExample)
MA (1) MA34581B1 (enExample)
MX (1) MX2013002602A (enExample)
MY (1) MY162768A (enExample)
NZ (1) NZ607630A (enExample)
PE (2) PE20131138A1 (enExample)
PH (1) PH12013500429A1 (enExample)
SG (2) SG10201506927TA (enExample)
TN (1) TN2013000087A1 (enExample)
TW (1) TWI576245B (enExample)
UA (1) UA110217C2 (enExample)
UY (1) UY33590A (enExample)
WO (1) WO2012031985A1 (enExample)
ZA (1) ZA201301389B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (enExample) * 1987-04-02 1990-06-29 Ciba Geigy Ag
DE58909570D1 (de) 1988-10-27 1996-02-22 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
MX9101787A (es) 1990-10-29 1992-06-05 Alza Corp Formulaciones,metodos y dispositivos anticonceptivos transdermicos
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
NZ518723A (en) 1999-11-24 2004-04-30 Agile Therapeutics Inc Improved transdermal contraceptive delivery system and process
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
AU2002235155A1 (en) 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
EP1216699A1 (de) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsystem enthaltend ein hochpotentes Gestagen
US20030165547A1 (en) * 2001-05-18 2003-09-04 Elisabeth Picard-Lesboueyries Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
ME00147B (me) * 2003-02-21 2010-10-10 Schering Ag Uv-stabilni transdermalni flasteri
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
JP4965263B2 (ja) 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
MX2007004315A (es) * 2004-10-08 2008-03-11 Noven Pharma Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo.
DE102004062182B4 (de) 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
AU2009302853B2 (en) * 2008-10-06 2014-09-11 Mylan Technologies, Inc. Amorphous rotigotine transdermal system

Also Published As

Publication number Publication date
IL224980A (en) 2017-07-31
PE20180198A1 (es) 2018-01-26
JP2016216500A (ja) 2016-12-22
AU2011298892B2 (en) 2015-03-12
US20140018751A1 (en) 2014-01-16
MY162768A (en) 2017-07-14
JP6104800B2 (ja) 2017-03-29
US20120082714A1 (en) 2012-04-05
TN2013000087A1 (en) 2014-06-25
PE20131138A1 (es) 2013-10-26
AP2013006787A0 (en) 2013-04-30
ZA201301389B (en) 2021-05-26
SG187941A1 (en) 2013-04-30
MX2013002602A (es) 2013-04-08
TW201217165A (en) 2012-05-01
EP2613771A1 (de) 2013-07-17
IL251124B (en) 2020-07-30
UA110217C2 (en) 2015-12-10
CU20130031A7 (es) 2013-05-31
IL251124A0 (en) 2017-04-30
EA032575B1 (ru) 2019-06-28
GT201300062A (es) 2015-01-16
JP2013536828A (ja) 2013-09-26
TWI576245B (zh) 2017-04-01
CO6690753A2 (es) 2013-06-17
WO2012031985A1 (de) 2012-03-15
AU2011298892A1 (en) 2013-03-28
US8557279B2 (en) 2013-10-15
US9060955B2 (en) 2015-06-23
CN103079549B (zh) 2016-11-02
ECSP13012477A (es) 2013-04-30
CR20130098A (es) 2013-05-15
AP3586A (en) 2016-02-10
BR112013005305A2 (pt) 2016-08-16
NZ607630A (en) 2015-02-27
DOP2013000053A (es) 2013-07-15
CN103079549A (zh) 2013-05-01
CA2810103A1 (en) 2012-03-15
EA201390246A1 (ru) 2013-09-30
PH12013500429A1 (en) 2019-10-07
KR20130114127A (ko) 2013-10-16
CL2013000636A1 (es) 2013-09-13
CU24172B1 (es) 2016-04-25
UY33590A (es) 2011-10-31
MA34581B1 (fr) 2013-10-02
CA2810103C (en) 2019-06-18
DE102010040299A1 (de) 2012-03-08
SG10201506927TA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
ES2578800T3 (es) Módulo fotovoltaico que comprende un elemento de conversión espectral localizado y procedimiento de realización
MX2012014060A (es) Sistema de suministro de ingredientes activos.
CL2011002968A1 (es) Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion.
AU2011336397A8 (en) Chemokine CXCR4 receptor modulators and uses related thereto
BR112013030592A2 (pt) estrutura absorvente para artigos absorventes
AR114086A2 (es) Polvos para reconstitución
MX2017000429A (es) Lengüetas de sujecion.
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
PH12015502280A1 (en) Transdermal delivery system comprising donepezil or its salt
PH12012501523A1 (en) Dental strip for administration of oral treatment
TW201129470A (en) Surface protective sheet
AR082907A1 (es) Sistemas terapeuticos transdermicos con lamina de proteccion inhibidora de la cristalizacion (release liner)
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
BR112015001621A2 (pt) dispositivo de distribuição
BR112014013878A8 (pt) emplastro
CL2013000335A1 (es) Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension.
AR085060A1 (es) Composiciones para el tratamiento del cabello con un adhesivo acrilico sensible a la presion
WO2012111996A3 (ko) 갈란타민 또는 그의 염을 함유하는 경피흡수제제
CL2009000326A1 (es) Forma de dosificacion unitaria que comprende una matriz de pelicula delgada que comprende un polimero de matriz soluble en agua y de 10ug a 200 ug de estradiol, o un hidrato o de un ester, con un espesor menor de 300 um, util en una condicion fisica causada por niveles endogenos insuficientes de estrogenos.
JP2013536828A5 (enExample)
AR082683A1 (es) Una disposicion de detonacion y un dispositivo para uso en un sistema de detonacion
BR102014025178B8 (pt) Adesivos à base de acrilatos incorporados com extrato de própolis
AR070617A1 (es) Formulacion farmaceutica que comprende oxabispidinas/236
AR130558A2 (es) Composición farmacéutica que comprende ledipasvir y sofosbuvir, forma de dosificación farmacéutica y comprimido que la comprenden
RU2009131118A (ru) Наноразмерное анионо-дефектное вещество на основе оксида алюминия для люминесцентного дозиметра ионизирующих излучений

Legal Events

Date Code Title Description
FB Suspension of granting procedure